We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cerebrolysin.
- Authors
Plosker, Greg L.; Gauthier, Serge
- Abstract
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability. A large, randomized comparison of Cerebrolysin, donepezil or combination therapy showed beneficial effects on global measures and cognition for all three treatment groups compared with baseline. Although not as extensively studied in patients with vascular dementia, Cerebrolysin has also shown beneficial effects on global measures and cognition in this patient population. Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) being the most frequently reported adverse event. Although further studies with Cerebrolysin, including longer term trials and further exploration of its use in combination with cholinesterase inhibitors, are needed to more clearly determine its place in the management of Alzheimer's disease and vascular dementia, available data suggest that Cerebrolysin is a useful addition to the treatment options available for dementia.
- Subjects
COGNITION disorders treatment; VASCULAR dementia; ALZHEIMER'S disease treatment; PEPTIDES; CHOLINESTERASE inhibitors; THERAPEUTICS
- Publication
Drugs & Aging, 2009, Vol 26, Issue 11, p893
- ISSN
1170-229X
- Publication type
Article
- DOI
10.2165/11203320-000000000-00000